UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 2, 2026
Picard Medical, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-42801 |
86-3212894 |
||
|
(State or other jurisdiction of incorporation) |
(Commission |
(IRS Employer Identification No.) |
|
1992 E Silverlake |
|
(Address of principal executive offices, including zip code) |
Registrant’s telephone number, including area code: (520) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
|
Common Stock, par value $0.0001 per share |
PMI |
The NYSE American, LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
8.01: Other Events
On July 2, 2026, Picard Medical, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the availability of a pre-recorded presentation (the “Presentation”) in advance of the Company's 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. A copy of each of the Press Release and Presentation is furnished as Exhibit 99.1 and Exhibit 99.2 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are being filed herewith:
|
Exhibit No. |
Description |
|
|
99.1 |
||
| 99.2 | Presentation, dated July 2, 2026 | |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Picard Medical, Inc. |
|||
|
By: |
/s/ Richard Fang |
||
|
Name: |
Richard Fang |
||
|
Title: |
Interim Chief Executive Officer |
||
Dated: July 2, 2026